Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

Nan Jin; Mengjie Yu; Xiaoyue Du; Zhiguo Wu; Changlin Zhai; Haihua Pan; Jinping Gu; Baogang Xie

doi:10.1186/s12872-023-03171-5

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

BMC Cardiovasc Disord. 2023 Mar 29;23(1):167. doi: 10.1186/s12872-023-03171-5.

Authors

Nan Jin^#¹, Mengjie Yu^#^{2

3}, Xiaoyue Du^#², Zhiguo Wu³, Changlin Zhai⁴, Haihua Pan⁴, Jinping Gu⁵, Baogang Xie^{6

7}

Affiliations

¹ College of Pharmaceutical Sciences, Zhejiang University of Technology, Zhejiang, China.
² Key laboratory of medical electronics and digital health of Zhejiang Province, Medical College of Jiaxing University, Jiaxing University, Jiaxing, China.
³ The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, China.
⁴ Department of Cardiovascular Diseases, Institute of Atherosclerosis, the Affiliated hospital of Jiaxing University, Jiaxing, China.
⁵ College of Pharmaceutical Sciences, Zhejiang University of Technology, Zhejiang, China. Jinpinggu@zjut.edu.cn.
⁶ College of Pharmaceutical Sciences, Zhejiang University of Technology, Zhejiang, China. xiebaogang49@zjxu.edu.cn.
⁷ Key laboratory of medical electronics and digital health of Zhejiang Province, Medical College of Jiaxing University, Jiaxing University, Jiaxing, China. xiebaogang49@zjxu.edu.cn.

^# Contributed equally.

Abstract

Background: Pulmonary arterial hypertension is a common complication in patients with congenital heart disease. In the absence of early diagnosis and treatment, pediatric patients with PAH has a poor survival rate. Here, we explore serum biomarkers for distinguishing children with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) from CHD.

Methods: Samples were analyzed by nuclear magnetic resonance spectroscopy-based metabolomics and 22 metabolites were further quantified by ultra-high-performance liquid chromatography-tandem mass spectroscopy.

Results: Serum levels of betaine, choline, S-Adenosyl methionine (SAM), acetylcholine, xanthosine, guanosine, inosine and guanine were significantly altered between CHD and PAH-CHD. Logistic regression analysis showed that combination of serum SAM, guanine and N-terminal pro-brain natriuretic peptide (NT-proBNP), yielded the predictive accuracy of 157 cases was 92.70% with area under the curve of the receiver operating characteristic curve value of 0.9455.

Conclusion: We demonstrated that a panel of serum SAM, guanine and NT-proBNP is potential serum biomarkers for screening PAH-CHD from CHD.

Keywords: Biomarkers; Children with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD); Metabolomics; Nuclear magnetic resonance; UPLC-MS/MS.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Child
Familial Primary Pulmonary Hypertension
Heart Defects, Congenital* / complications
Heart Defects, Congenital* / diagnosis
Humans
Hypertension, Pulmonary*
Metabolomics
Natriuretic Peptide, Brain
Peptide Fragments
Pulmonary Arterial Hypertension* / complications
Pulmonary Arterial Hypertension* / diagnosis

Substances

Biomarkers
Natriuretic Peptide, Brain
Peptide Fragments